Skip to content
Search

Latest Stories

Covid jab protection wanes within six months, UK researchers say

Covid jab protection wanes within six months, UK researchers say

PROTECTION against Covid-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

After five to six months, the effectiveness of the Pfizer jab at preventing Covid-19 infection in the month after the second dose fell from 88 per cent to 74 per cent, an analysis of data collected in Britain's ZOE COVID study showed.


For the AstraZeneca vaccine, effectiveness fell from 77 per cent to 67 per cent after four to five months.

The study was based on data from more than 1.2 million test results.

Previous analysis of data has suggested that vaccines provide protection for at least six months.

Under a worst-case scenario, protection could fall below 50 per cent for older people and healthcare workers by the winter, Tim Spector, principal investigator for the ZOE COVID study, said.

"It's bringing into focus this need for some action. We can't just sit by and see the protectiveness slowly waning whilst cases are still high and the chance of infection still high as well," Spector told BBC television.

Britain is starting to plan for a Covid-19 vaccine booster campaign later this year after top vaccine advisers said it might be necessary to give third shots to the elderly and most vulnerable from September.

(Reuters)

More For You

NHS

NHS ranks among worst for treatable deaths despite £242 billion spending

Getty Images

NHS ranks among worst for treatable deaths despite £242 billion spending

  • UK ranks among worst for treatable mortality, ahead of only US in global analysis.
  • NHS spending has reached £242 billion, but infrastructure gaps persist.
  • Shortage of scanners, beds and delays in care continue to affect outcomes.

The NHS is facing renewed scrutiny after a major international analysis suggested that UK patient survival rates remain among the weakest in developed healthcare systems, despite record levels of spending.

The report, led by the Institute for Public Policy Research, found that the UK ranks near the bottom among 22 countries for treatable mortality, a measure of deaths that could potentially be avoided with timely and effective care. Only the US performed worse.

Keep ReadingShow less